WO2003020259A3 - Combinations of dmxaa and other anti-cancer agents - Google Patents

Combinations of dmxaa and other anti-cancer agents Download PDF

Info

Publication number
WO2003020259A3
WO2003020259A3 PCT/GB2002/004025 GB0204025W WO03020259A3 WO 2003020259 A3 WO2003020259 A3 WO 2003020259A3 GB 0204025 W GB0204025 W GB 0204025W WO 03020259 A3 WO03020259 A3 WO 03020259A3
Authority
WO
WIPO (PCT)
Prior art keywords
combinations
dmxaa
cancer agents
topoisomerase
inhibitors
Prior art date
Application number
PCT/GB2002/004025
Other languages
French (fr)
Other versions
WO2003020259A2 (en
Inventor
William Robert Wilson
Bronwyn Gae Siim
Original Assignee
Cancer Rec Tech Ltd
William Robert Wilson
Bronwyn Gae Siim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to JP2003524567A priority Critical patent/JP2005509599A/en
Priority to SI200230798T priority patent/SI1423105T1/en
Application filed by Cancer Rec Tech Ltd, William Robert Wilson, Bronwyn Gae Siim filed Critical Cancer Rec Tech Ltd
Priority to MXPA04002004A priority patent/MXPA04002004A/en
Priority to NZ531045A priority patent/NZ531045A/en
Priority to BR0212258-8A priority patent/BR0212258A/en
Priority to CA002458459A priority patent/CA2458459A1/en
Priority to AU2002324143A priority patent/AU2002324143B2/en
Priority to EP02758562A priority patent/EP1423105B9/en
Priority to IL16017802A priority patent/IL160178A0/en
Priority to DE60230159T priority patent/DE60230159D1/en
Priority to DK02758562T priority patent/DK1423105T3/en
Priority to EA200400370A priority patent/EA008056B1/en
Publication of WO2003020259A2 publication Critical patent/WO2003020259A2/en
Publication of WO2003020259A3 publication Critical patent/WO2003020259A3/en
Priority to IS7144A priority patent/IS7144A/en
Priority to NO20040591A priority patent/NO20040591L/en
Priority to US10/790,943 priority patent/US7863322B2/en
Priority to US11/592,678 priority patent/US20070060637A1/en
Priority to US11/830,659 priority patent/US7868040B2/en
Priority to US11/830,677 priority patent/US7863321B2/en
Priority to US11/830,668 priority patent/US7863320B2/en
Priority to US11/830,650 priority patent/US7868039B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to synergistic combinations of the compound 5,6-dimethylxanthenone-4-acetic acid (DMXAA) and a compound selected from platinum compounds, vinca alkaloids, alkylating agents, anthracyclines, topoisomerase I inhibitors, antimetabolites and topoisomerase II inhibitors, which have anti-tumour activity. More particularly, the invention is concerned with the use of such combinations in the treatment of cancer and pharmaceutical compounds containing said combinations.
PCT/GB2002/004025 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents WO2003020259A2 (en)

Priority Applications (20)

Application Number Priority Date Filing Date Title
DK02758562T DK1423105T3 (en) 2001-09-03 2002-09-03 Compositions of DMXAA and other anticancer agents
DE60230159T DE60230159D1 (en) 2001-09-03 2002-09-03 COMPOSITIONS OF DMXAA AND OTHER ANTICROBIAL AGENTS
MXPA04002004A MXPA04002004A (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents.
NZ531045A NZ531045A (en) 2001-09-03 2002-09-03 Combination of the anti-cancer agents DMXAA and gemcitabine
BR0212258-8A BR0212258A (en) 2001-09-03 2002-09-03 Anti-Cancer Combinations
CA002458459A CA2458459A1 (en) 2001-09-03 2002-09-03 Anti-cancer combinations
SI200230798T SI1423105T1 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents
EP02758562A EP1423105B9 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents
EA200400370A EA008056B1 (en) 2001-09-03 2002-09-03 Anti-cancer combinations
JP2003524567A JP2005509599A (en) 2001-09-03 2002-09-03 Anti-cancer combination
AU2002324143A AU2002324143B2 (en) 2001-09-03 2002-09-03 Combinations of dxmaa and other anti-cancer agents
IL16017802A IL160178A0 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents
IS7144A IS7144A (en) 2001-09-03 2004-02-06 Anticancer drugs
NO20040591A NO20040591L (en) 2001-09-03 2004-02-10 Combination compounds for the treatment of cancer.
US10/790,943 US7863322B2 (en) 2001-09-03 2004-03-02 Anti-cancer combinations
US11/592,678 US20070060637A1 (en) 2001-09-03 2006-11-03 Anti-cancer combinations
US11/830,659 US7868040B2 (en) 2001-09-03 2007-07-30 Anti-cancer combinations
US11/830,677 US7863321B2 (en) 2001-09-03 2007-07-30 Anti-cancer combinations
US11/830,668 US7863320B2 (en) 2001-09-03 2007-07-30 Anti-cancer combinations
US11/830,650 US7868039B2 (en) 2001-09-03 2007-07-30 Anti-cancer combinations

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0121285.1A GB0121285D0 (en) 2001-09-03 2001-09-03 Anti-cancer combinations
GB0121285.1 2001-09-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/790,943 Continuation-In-Part US7863322B2 (en) 2001-09-03 2004-03-02 Anti-cancer combinations

Publications (2)

Publication Number Publication Date
WO2003020259A2 WO2003020259A2 (en) 2003-03-13
WO2003020259A3 true WO2003020259A3 (en) 2003-04-17

Family

ID=9921418

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2002/004025 WO2003020259A2 (en) 2001-09-03 2002-09-03 Combinations of dmxaa and other anti-cancer agents

Country Status (23)

Country Link
US (6) US7863322B2 (en)
EP (3) EP2236134A1 (en)
JP (3) JP2005509599A (en)
CN (5) CN101596187A (en)
AT (1) ATE415963T1 (en)
AU (1) AU2002324143B2 (en)
BR (1) BR0212258A (en)
CA (1) CA2458459A1 (en)
CY (1) CY1110426T1 (en)
DE (1) DE60230159D1 (en)
DK (1) DK1423105T3 (en)
EA (3) EA010857B1 (en)
ES (1) ES2321283T3 (en)
GB (1) GB0121285D0 (en)
IL (1) IL160178A0 (en)
IS (1) IS7144A (en)
MX (1) MXPA04002004A (en)
NO (1) NO20040591L (en)
NZ (5) NZ546573A (en)
PT (1) PT1423105E (en)
SI (1) SI1423105T1 (en)
WO (1) WO2003020259A2 (en)
ZA (1) ZA200401078B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709416B2 (en) 2008-08-25 2014-04-29 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
DE60027719T2 (en) * 1999-06-14 2007-04-26 Cancer Research Technology Ltd. CANCER THERAPY
MXPA02011319A (en) 2000-05-15 2003-06-06 Pharma Mar Sa Antitumoral analogs of et 743.
JP2004505047A (en) 2000-07-28 2004-02-19 キャンサー・リサーチ・テクノロジー・リミテッド Cancer treatment by combined therapy
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB0202544D0 (en) 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB2386836B (en) * 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
PT1689404E (en) 2003-11-13 2008-12-15 Pharma Mar Sau Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer
PL1658848T3 (en) 2004-10-29 2007-12-31 Pharma Mar Sa Formulations comprising ecteinascidin and a disaccharide
KR20080047402A (en) * 2005-08-26 2008-05-28 안티소마 피엘씨 Combinations comprising dmxaa for the treatment of cancer
GB0517387D0 (en) * 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
GB0625283D0 (en) * 2006-12-19 2007-01-24 Cyclacel Ltd Combination
US20100272717A1 (en) * 2007-12-13 2010-10-28 Novartis Ag Combinations of therapeutic agents for treating cancer
CN101279967B (en) * 2008-05-29 2010-11-10 武汉远大制药集团有限公司 Medicinal composition of trimethyl xanthone-4-acetic acid for treating cancer and use thereof
US20100068302A1 (en) * 2008-09-17 2010-03-18 Traslational Cancer Drugs Pharma, S.L. Methods and compositions for the treatment of cancer
WO2011019782A1 (en) * 2009-08-11 2011-02-17 Novartis Ag Combinations of vascular disrupting agents with inhibitor of apoptosis proteins antagonists
ES2609931T3 (en) 2010-06-18 2017-04-25 Myriad Genetics, Inc. Methods and materials to evaluate the loss of heterozygosity
NZ606725A (en) 2010-08-24 2014-06-27 Dana Farber Cancer Inst Inc Methods for predicting anti-cancer response
CN105906602B (en) * 2011-05-16 2018-07-10 杭州民生药物研究院有限公司 The preparation method of 2- (5,6- dimethylxanthene ketone -4- bases)-acetogenin
JP6117194B2 (en) 2011-06-17 2017-04-19 ミリアド・ジェネティックス・インコーポレイテッド Methods and materials for assessing allelic imbalance
CA2860312C (en) 2011-12-21 2022-07-12 Myriad Genetics, Inc. Methods and materials for assessing loss of heterozygosity
EP2617421A1 (en) * 2012-01-20 2013-07-24 Isofol Medical AB Tetrahydrofolates in combination with EGFR-inhibitors in the use of treating cancer
NZ628813A (en) 2012-02-23 2015-10-30 Univ Denmark Tech Dtu Methods for predicting anti-cancer response
CA3126823C (en) 2012-06-07 2023-04-04 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
US10308986B2 (en) 2013-03-14 2019-06-04 Children's Medical Center Corporation Cancer diagnosis, treatment selection and treatment
AU2014248007B2 (en) 2013-04-05 2020-03-26 Myriad Genetics, Inc. Methods and materials for assessing homologous recombination deficiency
US20160067182A1 (en) * 2013-04-09 2016-03-10 Merrimack Pharmaceuticals, Inc. Methods and compositions for improving outcomes of liposomal chemotherapy
EP3071209A4 (en) * 2013-11-19 2017-08-16 The University of Chicago Use of sting agonist as cancer treatment
EP3080292B1 (en) 2013-12-09 2022-02-02 Institut Curie Methods for detecting inactivation of the homologous recombination pathway (brca1/2) in human tumors
JP6877334B2 (en) 2014-08-15 2021-05-26 ミリアド・ジェネティックス・インコーポレイテッド Methods and Materials for Assessing Homologous Recombination Defects
EP4141127A1 (en) 2021-08-30 2023-03-01 Zentrum Familiärer Brust- und Eierstockkrebs Universitätsklinik Köln Method for assessing homologous recombination deficiency in ovarian cancer cells
CN115282140B (en) * 2022-02-07 2024-03-08 南京市儿童医院 AKI therapeutic agent and use of DMXAA in preparation of the therapeutic agent

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023753A1 (en) * 1993-04-20 1994-10-27 Cancer Research Campaign Technology Limited Cancer therapy, using antibody conjugates, in combination with a vasoactive agent
US20010027210A1 (en) * 2000-03-03 2001-10-04 Wilson William R. Combination therapy for cancer
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3655470A (en) 1969-03-29 1972-04-11 Toa Gosei Chem Ind Process for the production of a foamed thermoplastic resin sheet
DE2015265A1 (en) 1969-03-29 1970-10-08 Yoshitomi Pharmaceutical Industries Ltd., Osaka (Japan) Arylalkanoic acids and processes for their preparation
US4565806A (en) * 1981-08-18 1986-01-21 Setaelae Kai M E Composition and method for rational treatment of cancer
FR2516922A1 (en) 1981-11-25 1983-05-27 Lipha ACIDS (OXO-4-4H- (1) -BENZOPYRAN-8-YL) ALKANOIC, SALTS AND DERIVATIVES, PREPARATION AND DRUG CONTAINING THEM
CA1264738A (en) * 1984-12-04 1990-01-23 Eli Lilly And Company Treatment of tumors in mammals
US4704355A (en) 1985-03-27 1987-11-03 New Horizons Diagnostics Corporation Assay utilizing ATP encapsulated within liposome particles
ATE102616T1 (en) 1986-12-23 1994-03-15 Warner Lambert Co COMPOUNDS WITH ANTITUMORAL AND ANTIBACTERIAL PROPERTIES.
US5281620A (en) 1986-12-23 1994-01-25 Cancer Research Campaign Technology Limited Compounds having antitumor and antibacterial properties
JPH01193227A (en) 1988-01-29 1989-08-03 Res Dev Corp Of Japan Adjuvant for cancer immunotherapy
US5126129A (en) 1988-05-23 1992-06-30 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health & Human Services Cancer therapy using interleukin-2 and flavone compounds
US5075287A (en) 1989-03-03 1991-12-24 Nisshin Oil Mills, Inc. Muramyl peptide derivatives and immunoregulating compositions containing them
WO1991004014A1 (en) 1989-09-21 1991-04-04 Synergen, Inc. Method for transporting compositions across the blood brain barrier
US5250296A (en) 1990-11-29 1993-10-05 Takeda Chemical Industries, Ltd. Immunostimulant agent containing interleukin-2 and 5'-deoxy-5-fluorouridine
EP0551200A1 (en) 1992-01-07 1993-07-14 National University Of Singapore Protein phosphatase inhibitors for use in therapy
CA2086874E (en) 1992-08-03 2000-01-04 Renzo Mauro Canetta Methods for administration of taxol
GB9320484D0 (en) 1993-10-05 1993-11-24 Wellcome Found Pharmaceutical combinations
DE4417742A1 (en) * 1994-05-20 1995-11-23 Bayer Ag Non-systemic control of parasites
US5620875A (en) 1995-02-17 1997-04-15 University Of Portland Transfer of taxol from yew tree cuttings into a culture medium over time
AU5688596A (en) 1995-04-13 1996-10-30 Deutsche Om Arzneimittel Gmbh Anti-cd14 antibodies for use in the induction of il-10 secre tion
WO1996036347A1 (en) 1995-05-17 1996-11-21 Eli Lilly And Company Use of leukotriene antagonists for alzheimer's disease
JPH0940690A (en) 1995-05-23 1997-02-10 Yutaka Sashita Steroid glycoside and medicine containing the same as active ingredient
AU6714396A (en) 1995-07-28 1997-02-26 Trustees Of Boston University Methods and compositions for treating cell proliferative disorders
US5977077A (en) 1995-08-28 1999-11-02 Interlab Corporation Xanthone analogs for the treatment of infectious diseases
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
WO1998025600A1 (en) 1996-12-13 1998-06-18 Eli Lilly And Company Leukotriene antagonists for treatment or inhibition of gout
JP2001509143A (en) 1996-12-13 2001-07-10 イーライ・リリー・アンド・カンパニー Leukotriene antagonists for cerebral focal stroke
UA47505C2 (en) 1996-12-13 2002-07-15 Елі Ліллі Енд Компані A method for treatment a flat-cell cancer of mouth cavity by means of leicotrien antagonists
EP0967987B1 (en) 1997-03-11 2003-06-04 Les Laboratoires Aeterna Inc. Compositions for treating tumors containing shark cartilage extracts and anti-neoplastic agents
WO1998042346A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating ischemia reperfusion injury
US5914340A (en) 1997-03-21 1999-06-22 Eli Lilly And Company Leukotriene antagonists useful for treating dermatoses
WO1998042345A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cerebral focal stroke
HUP9904672A2 (en) 1997-03-21 2000-05-28 Eli Lilly And Co. Leukotriene antagonists for oral squamous cell carcinoma
WO1998042336A1 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating gingivitis
WO1998042650A2 (en) 1997-03-21 1998-10-01 Eli Lilly And Company Leukotriene antagonists useful for treating cystic fibrosis
AU6450498A (en) 1997-03-21 1998-10-20 Eli Lilly And Company Leukotriene antagonists useful for treating gout
US5998454A (en) 1997-03-21 1999-12-07 Eli Lilly And Company Leukotriene antagonists useful for treating iritis
DE19721211A1 (en) 1997-05-21 1998-11-26 Lindner Sen Wolfgang Dr Med Three-fold treatment of tumours providing synergistic effect
EP1107784A2 (en) 1998-08-24 2001-06-20 Maxim Pharmaceuticals, Inc. Activation and protection of t-cells (cd4?+ and cd8?+ ) using an h 2? receptor agonist and other t-cell activating agents
AU757649B2 (en) 1998-09-10 2003-02-27 Genaera Corporation Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities
AUPP609198A0 (en) 1998-09-22 1998-10-15 Curtin University Of Technology Use of non-peptidyl compounds for the treatment of insulin related ailments
US6174873B1 (en) 1998-11-04 2001-01-16 Supergen, Inc. Oral administration of adenosine analogs
GB9903404D0 (en) 1999-02-16 1999-04-07 Angiogene Pharm Ltd Methods of treatment and compositions useful for the treatment of diseases involving angiogenesis
DE60018225T2 (en) 1999-03-01 2005-12-29 Pfizer Products Inc., Groton Oxamic acids having a cyano group as ligands for the thyroid receptor
DE60027719T2 (en) 1999-06-14 2007-04-26 Cancer Research Technology Ltd. CANCER THERAPY
US6806257B1 (en) 1999-10-20 2004-10-19 Board Of Trustees Of Southern Illinois University Flavones as inducible nitric oxide synthase inhibitors, cyclooxygenase-2 inhibitors and potassium channel activators
NZ517667A (en) 1999-11-11 2004-05-28 Lilly Co Eli Oncolytic combinations for the treatment of cancer
WO2001034197A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
WO2001034198A2 (en) 1999-11-11 2001-05-17 Eli Lilly And Company Oncolytic combinations for the treatment of cancer
JP2003513914A (en) 1999-11-11 2003-04-15 イーライ・リリー・アンド・カンパニー Oncolytic drug combinations for the treatment of cancer
JP2003522790A (en) 2000-02-17 2003-07-29 メルク エンド カムパニー インコーポレーテッド Treatment or prevention of prostate cancer using a COX-2 selective inhibitor
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
GB2386836B (en) 2002-03-22 2006-07-26 Cancer Res Ventures Ltd Anti-cancer combinations
GB2394658A (en) 2002-11-01 2004-05-05 Cancer Rec Tech Ltd Oral anti-cancer composition
GB0321999D0 (en) 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
GT200500186A (en) * 2004-07-07 2006-03-02 ANTI-CONTRACEPTIVE REGIMES WITH PROGESTERONE RECEPTOR ANTAGONISTS AND KITS
GB0517387D0 (en) 2005-08-26 2005-10-05 Antisoma Res Ltd Combinations for the treatment of cancer
KR20080047402A (en) 2005-08-26 2008-05-28 안티소마 피엘씨 Combinations comprising dmxaa for the treatment of cancer
JP2011500773A (en) 2007-10-23 2011-01-06 アンティソーマ・リサーチ・リミテッド Crystal form of DMXAA sodium salt

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994023753A1 (en) * 1993-04-20 1994-10-27 Cancer Research Campaign Technology Limited Cancer therapy, using antibody conjugates, in combination with a vasoactive agent
US20010027210A1 (en) * 2000-03-03 2001-10-04 Wilson William R. Combination therapy for cancer
WO2002009700A1 (en) * 2000-07-28 2002-02-07 Cancer Research Technology Limited Cancer treatment by combination therapy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HILL, S A; SAMPSON, L E; CHAPLIN, D A: "Anti-vascular approaches to solid tumour therapy: Evaluation of vinblastine and flavone acetic acid", INTERNATIONAL JOURNAL OF CANCER, vol. 63, no. 1, 1995, pages 119 - 123, XP009003224 *
REWCASTLE, G W; ATWELL, G J; ZHUANG, L; BAGULEY, B C; DENNY, W A: "Potential Antitumour Agents. 61. Structure-Activity Relationships for in Vivo Colon 38 Activity among Disubstituted 9-Oxo-9H-xanthene-4-acetic acids.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 34, no. 1, 1991, pages 217 - 222, XP002226304 *
SIEMANN, D W; MERCER, E; LEPLER, S; ROJIANI, A M: "Vascular targetting Agents Enhance Chemotherapeutic Agent Activities in Solid Tumour Therapy", INTERNATION JOURNAL OF CANCER, vol. 99, 2002, pages 1 - 6, XP002226322 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8709416B2 (en) 2008-08-25 2014-04-29 Amplimmune, Inc. Compositions of PD-1 antagonists and methods of use

Also Published As

Publication number Publication date
SI1423105T1 (en) 2009-08-31
WO2003020259A2 (en) 2003-03-13
ZA200401078B (en) 2005-04-15
EP1423105A2 (en) 2004-06-02
EP1423105B1 (en) 2008-12-03
JP2010270124A (en) 2010-12-02
EP1423105B9 (en) 2009-08-12
US20080070886A1 (en) 2008-03-20
EA200601118A1 (en) 2006-12-29
CN100536840C (en) 2009-09-09
US20070060637A1 (en) 2007-03-15
JP2005509599A (en) 2005-04-14
NZ567456A (en) 2009-08-28
GB0121285D0 (en) 2001-10-24
NZ546573A (en) 2007-05-31
NO20040591L (en) 2004-04-30
CN101607087A (en) 2009-12-23
US20080070848A1 (en) 2008-03-20
US7868039B2 (en) 2011-01-11
US7868040B2 (en) 2011-01-11
EA200400370A1 (en) 2004-08-26
JP2009263371A (en) 2009-11-12
IL160178A0 (en) 2004-07-25
EA200801611A1 (en) 2009-06-30
PT1423105E (en) 2009-03-09
EA010857B1 (en) 2008-12-30
DK1423105T3 (en) 2009-03-30
EP1759694A3 (en) 2009-02-18
US20080070849A1 (en) 2008-03-20
CN101596187A (en) 2009-12-09
ATE415963T1 (en) 2008-12-15
EP2236134A1 (en) 2010-10-06
US20040204480A1 (en) 2004-10-14
CY1110426T1 (en) 2015-04-29
CN1994287A (en) 2007-07-11
IS7144A (en) 2004-02-06
NZ554093A (en) 2008-07-31
NZ576925A (en) 2010-07-30
AU2002324143B2 (en) 2007-09-13
US7863321B2 (en) 2011-01-04
NZ531045A (en) 2006-08-31
CN101596186A (en) 2009-12-09
US7863322B2 (en) 2011-01-04
BR0212258A (en) 2004-10-19
DE60230159D1 (en) 2009-01-15
US7863320B2 (en) 2011-01-04
MXPA04002004A (en) 2005-02-17
EA008056B1 (en) 2007-02-27
EP1759694A2 (en) 2007-03-07
US20080070847A1 (en) 2008-03-20
CA2458459A1 (en) 2003-03-13
ES2321283T3 (en) 2009-06-04
CN1708296A (en) 2005-12-14

Similar Documents

Publication Publication Date Title
WO2003020259A3 (en) Combinations of dmxaa and other anti-cancer agents
CA2480800A1 (en) Inhibitors of akt activity
CA2442270A1 (en) Inhibitors of akt activity
WO2003086279A3 (en) Inhibitors of akt activity
HK1068136A1 (en) Muscarinic antagonists
WO2005037825A3 (en) Protein kinase inhibitors
CA2188043A1 (en) 7,11 disubstituted camptothecin derivatives, formulations containing such derivatives and their use
WO2004096131A3 (en) Inhibitors of akt activity
WO2004096135A3 (en) Inhibitors of akt activity
MY117948A (en) Nitride oxide synthase inhibitors.
WO1994007479A3 (en) Immunopotentiatory agents
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
WO2001087882A3 (en) Substituted pyrrolopyridinone derivatives useful as phosphodiesterase inhibitors
HK1085675A1 (en) Anticancer compounds
ES2154560A1 (en) Use of chromanes and/or chromenes derivatives to prevent oxidative reactions induced by free radicals
BR0208017A (en) Combination comprising combretastatin and anticancer agents
WO2003028721A3 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
WO2004034976A3 (en) Dihydroartemisinin and dihydroartemisitene dimers as anti-cancer nd anti-infective agents
AP2001002191A0 (en) 3,3- Biarylpiperine and 2,2-biarylmorpholine derivatives.
BR0116123A (en) Antitumor Carbazoles
GB0127568D0 (en) Chemical compounds
BR0000901A (en) 4-phenyl-4-heteroarylpiperidine derivatives
WO2003061598A3 (en) Solenopsin a, b and analogs as novel angiogenesis inhibitors
WO2005023741A3 (en) Pharmaceutical compositions containing (+) cannabidiol and derivatives thereof and some such novel derivatives
CA2426754A1 (en) Indolocarbazole anticancer agents and methods of using them

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002324143

Country of ref document: AU

Ref document number: 160178

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 531045

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2004/01078

Country of ref document: ZA

Ref document number: 200401078

Country of ref document: ZA

WWE Wipo information: entry into national phase

Ref document number: 2458459

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: PA/a/2004/002004

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 20028172574

Country of ref document: CN

Ref document number: 2003524567

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2002758562

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 200400370

Country of ref document: EA

WWP Wipo information: published in national office

Ref document number: 2002758562

Country of ref document: EP